TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8635375

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, qid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (2 mg, qid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1727685

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Naloxone (0.075 mg/kg i.v.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6635761

Group type: EXPERIMENTAL
Intervention: Praziquantel 15 mg/kg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg/kg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 85
Study: 31109849

Group type: EXPERIMENTAL
Intervention: Call center management for acute HAE attacks
Number of subjects: 100
Study: 27425824

Group type: COMPARATOR
Intervention: NTP-CE (topical panthenol-containing emollient)
Number of subjects: 23
Study: 25259540

Group type: EXPERIMENTAL
Intervention: Aerobic training (3 d·wk⁻¹ for 40 min at 75%-85% HR reserve for 12 wk) in TL group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic training (3 d·wk⁻¹ for 40 min at 75%-85% HR reserve for 12 wk) in TH group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic training in TL group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic training in TL and TH groups
Number of subjects: 40
Study: 22311659

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied (670 nm, 5 mW, 2 J/cm², 16 min, 5 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 300
Study: 21083596

Group type: EXPERIMENTAL
Intervention: rabeprazole 5 mg/day
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg/day
Number of subjects: 288

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 288
Study: 19137369

Group type: EXPERIMENTAL
Intervention: Platinum-fibered microcoils
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amplatzer Vascular Plug II (AVP II)
Number of subjects: 50
Study: 17470824

Group type: EXPERIMENTAL
Intervention: Adalimumab (160 mg at week 0 and 80 mg at week 2)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 325
Study: 15887477

Group type: EXPERIMENTAL
Intervention: Training in cardiovascular (CV) prevention during a CME meeting
Number of subjects: 343
Study: 12000496

Group type: EXPERIMENTAL
Intervention: Active treatment with 1% benzyl benzoate and 1% tannic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment (first treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active treatment (second treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 30
Study: 11382858

Group type: EXPERIMENTAL
Intervention: Bilateral pallidotomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pre-operative condition
Number of subjects: 23
Study: 7900630

Group type: EXPERIMENTAL
Intervention: Urodilatin (15 ng/kg/min for 10 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2729162

Group type: EXPERIMENTAL
Intervention: Glucose absorption in NIDDM subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glycine absorption in NIDDM subjects
Number of subjects: 21

Group type: COMPARATOR
Intervention: Glucose absorption in healthy volunteers
Number of subjects: 21

Group type: COMPARATOR
Intervention: Glycine absorption in healthy volunteers
Number of subjects: 21
Study: 30034

Group type: EXPERIMENTAL
Intervention: 10 mg Pindolol and 5 mg Clopamid (VKB 105)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: VKB 105 (Pindolol and Clopamid)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: VKB 105
Number of subjects: 678
Study: 29980654

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings (PHWs) placed on waterpipe devices
Number of subjects: 90
Study: 28139100

Group type: EXPERIMENTAL
Intervention: Ozurdex® implant (PRN group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ozurdex® implant (fixed group)
Number of subjects: 42
Study: 25599540

Group type: EXPERIMENTAL
Intervention: Variable spot scanning (VSS) ablation with the VISX STAR S4/IR platform
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation profile with the WaveLight Allegretto Wave Eye‐Q platform
Number of subjects: 50
Study: 23381501

Group type: EXPERIMENTAL
Intervention: Group A (immediate treatment)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group B (no treatment for 3 months)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (long-term follow-up)
Number of subjects: 64
Study: 22137084

Group type: COMPARATOR
Intervention: Basic support (nurse-led disease management program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive support (nurse-led disease management program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (routine follow-up by a cardiologist)
Number of subjects: 0
Study: 18669576

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18206037

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of anisodamine (200 microg/ml)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard therapy (Control group B)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of anisodamine
Number of subjects: 47
Study: 16004744

Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information video plus leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 0
Study: 12402200

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study: 9815053

Group type: EXPERIMENTAL
Intervention: Gastrin-17 (20 pmol. kg‐1. h‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (gastric acid inhibition)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 7
Study: 8715223

Group type: EXPERIMENTAL
Intervention: 5% propolis vaginal dressings applied for 10 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lugol daily dressings applied for 10 consecutive days
Number of subjects: 0
Study: 2710561

Group type: EXPERIMENTAL
Intervention: gallamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 9

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 9
Study: 340158

Group type: EXPERIMENTAL
Intervention: Propranolol 80 to 160 mg daily
Number of subjects: 10
Study: 31366275

Group type: EXPERIMENTAL
Intervention: Pain Threat
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cognitive Threat with Control
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pain Threat with Control
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pain-related fear
Number of subjects: 146
Study: 30565426

Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (12 g/day for 14 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 27286893

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg)
Number of subjects: 32
Study: 24996893

Group type: EXPERIMENTAL
Intervention: Aspheric toric intraocular lens (Lentis L‐312T)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aspheric nontoric intraocular lens (Lentis L‐312) with opposite clear corneal incision (OCCI)
Number of subjects: 55
Study: 22832724

Group type: EXPERIMENTAL
Intervention: Circular plus ventral upward infiltration
Number of subjects: 89

Group type: COMPARATOR
Intervention: Circular infiltration
Number of subjects: 89

Group type: COMPARATOR
Intervention: Circular plus dorsal penile infiltration
Number of subjects: 89
Study: 20499427

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 17587273

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (8 x 10(8) c.f.u./day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (50 mg/kg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15735561

Group type: EXPERIMENTAL
Intervention: Management in a Chest Pain Unit (CPU)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional management in a Coronary Care Unit (CCU)
Number of subjects: 210
Study: 11807965

Group type: EXPERIMENTAL
Intervention: 500 mg hawthorn extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: 600 mg Mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination of 600 mg Mg and 500 mg hawthorn extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10417463

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 20
Study: 7762285

Group type: EXPERIMENTAL
Intervention: 1 x 10(5) c.f.u. S. flexneri SFL1070
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 x 10(7) c.f.u. S. flexneri SFL1070
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 x 10(8) c.f.u. S. flexneri SFL1070
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 x 10(9) c.f.u. S. flexneri SFL1070
Number of subjects: 37
Study: 2283869

Group type: EXPERIMENTAL
Intervention: Explicit curriculum with designed activities and face-to-face teacher training
Number of subjects: 106

Group type: COMPARATOR
Intervention: Other three smoking prevention programs (not specified)
Number of subjects: 106
Study: 88753

Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy (12 mg/kg daily for 4 days, then 6 mg/kg on alternate days, followed by 12 mg/kg weekly for 1 year)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy
Number of subjects: 299
Study: 31665323

Group type: EXPERIMENTAL
Intervention: Treated SGTF (n = 125)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Overtreated SGTF (n = 40)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Normal gestational thyroid function (GTF) (n = 246)
Number of subjects: 475
Study: 31319398

Group type: EXPERIMENTAL
Intervention: Group-dynamics-based intervention (8-week duration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Individually supervised intervention (8-week duration)
Number of subjects: 23
Study: 28399551

Group type: EXPERIMENTAL
Intervention: Surgical treatment for degenerative spondylolisthesis (DS) including instrumented fusion (72%), noninstrumented fusion (21%), and decompression alone (7%).
Number of subjects: 406

Group type: COMPARATOR
Intervention: Nonreoperative patients
Number of subjects: 406
Study: 25460264

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (5-day, 10-session protocol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline standard inpatient treatment
Number of subjects: 6
Study: 23480783

Group type: EXPERIMENTAL
Intervention: Metformin (n = 24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Metformin plus Simvastatin (n = 18)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 21692586

Group type: EXPERIMENTAL
Intervention: Continuous Primary Nursing Care (CPNC)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Task-Centered Nursing Care (TCNC)
Number of subjects: 470
Study: 18957487

Group type: EXPERIMENTAL
Intervention: Infliximab (3 or 6 mg/kg) plus methotrexate (MTX)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 871
Study: 16763547

Group type: EXPERIMENTAL
Intervention: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone (0.16 mg/kg, subcutaneous injection, 3 cycles of 10 days over 3 months)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Number of subjects: 65
Study: 15123028

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.2 mg/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous diazepam 0.2 mg/kg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 70
Study: 11304782

Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 605

Group type: COMPARATOR
Intervention: Intravenous fluorouracil plus leucovorin (5‐FU/LV)
Number of subjects: 605
Study: 9481978

Group type: EXPERIMENTAL
Intervention: Group A: alfentanil, N2O, O2 with 0.25% isoflurane
Number of subjects: 119

Group type: COMPARATOR
Intervention: Group B: oxygen, room air, isoflurane, and alfentanil
Number of subjects: 119
Study: 8306013

Group type: EXPERIMENTAL
Intervention: Oxytocin plus ergometrine (Syntometrine: 5 units of oxytocin with 0.5 mg of ergometrine)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Oxytocin alone (5 units of Syntocinon)
Number of subjects: 461
Study: 3521532

Group type: EXPERIMENTAL
Intervention: Haloperidol (n = 21), mean dose 7.24 mg, 4 to 16 mg range
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Amitriptyline (n = 20), mean dose 147.62 mg, 100 to 175 mg range
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 61
Study: 29155807

Group type: EXPERIMENTAL
Intervention: Hypoallergenic, nutritionally complete amino-acid-based formula including a prebiotic blend of fructo-oligosaccharides and the probiotic strain Bifidobacterium breve M-16V (test group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Amino-acid-based formula without synbiotics (control group)
Number of subjects: 71
Study: 28486519

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Number of subjects: 1216
Study: 26700937

Group type: EXPERIMENTAL
Intervention: 40 mg of atorvastatin once daily for 2 years
Number of subjects: 350

Group type: COMPARATOR
Intervention: Identical placebo once daily for 2 years
Number of subjects: 350
Study: 22936298

Group type: EXPERIMENTAL
Intervention: Polyether (PE: Impregum Penta H/L DuoSoft Quick, 3 M ESPE) with manufacturer's recommended working time
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Addition-curing silicone (AS: Aquasil Ultra LV, Dentsply/DeTrey) with manufacturer's recommended working time
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Addition-curing silicone (AS) with altered working times
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polyether (PE) with altered working times
Number of subjects: 96
Study: 20645670

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-lithium
Number of subjects: 55
Study: 18972768

Group type: EXPERIMENTAL
Intervention: Early enteral feeding through a nasojejunal tube initiated 12 hours after surgery
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Early enteral feeding through a nasojejunal tube
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard care without early enteral feeding)
Number of subjects: 61
Study: 17006324

Group type: EXPERIMENTAL
Intervention: CsA plus atorvastatin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TRL alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TRL plus atorvastatin
Number of subjects: 12

Group type: COMPARATOR
Intervention: CsA alone
Number of subjects: 12
Study: 14698826

Group type: EXPERIMENTAL
Intervention: Ultrasound dating service
Number of subjects: 3009

Group type: COMPARATOR
Intervention: Control unit (obstetric ultrasound only for specific indications)
Number of subjects: 3009
Study: 12608196

Group type: EXPERIMENTAL
Intervention: Fuji IX glass-ionomer cement
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: Ketac-MOLAR (hand mix)
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: ART approach (general)
Number of subjects: 1325
Study: 9330931

Group type: EXPERIMENTAL
Intervention: Short‐Form Health Survey (SF‐36)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Joint tenderness score
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physician global assessment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patient global assessment
Number of subjects: 48
Study: 8376571

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 40
Study: 3532602

Group type: EXPERIMENTAL
Intervention: Heat-stable 17D yellow fever vaccine
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non-stabilized yellow fever vaccine
Number of subjects: 258
Study: 29128416

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 27058396

Group type: EXPERIMENTAL
Intervention: T'ai chi chuan
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 7
Study: 24606601

Group type: EXPERIMENTAL
Intervention: Self-management group intervention (eight weekly sessions, 90 minutes each)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 42
Study: 22353025

Group type: EXPERIMENTAL
Intervention: Self-monitoring (open vs. blinded Omron-HJ-113-E pedometer)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Goal-setting (step-count goal prompt vs. alternative goal prompt)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Goal-setting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Time
Number of subjects: 10
Study: 20507732

Group type: EXPERIMENTAL
Intervention: CIK cell transfusion (intravenously or via common hepatic arteries, every week for at least 4 times)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no CIK cell transfusion)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CIK cell transfusion
Number of subjects: 122
Study: 18728513

Group type: EXPERIMENTAL
Intervention: Mobilization at 3 hours after sheath removal
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Mobilization at 4 hours after sheath removal
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Mobilization at 6 hours after sheath removal
Number of subjects: 304
Study: 16372825

Group type: EXPERIMENTAL
Intervention: FEBT 200 microg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: FEBT 500 microg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: FEBT 810 microg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: FEBT 1080 microg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: FEBT 200-1080 microg
Number of subjects: 25
Study: 12090967

Group type: EXPERIMENTAL
Intervention: Rochester AIDS Prevention Project curriculum taught by peer educators
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Rochester AIDS Prevention Project curriculum taught by regular teachers
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Regular school health curriculum (Control)
Number of subjects: 1352
Study: 11156963

Group type: EXPERIMENTAL
Intervention: Resistance exercise for 3 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 2
Study: 9438888

Group type: EXPERIMENTAL
Intervention: Popliteal block (30 ml of alkalinized 3% chloroprocaine) and posterior cutaneous nerve of the thigh block (10 ml of 1% lidocaine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Spinal anesthesia (65 mg of 5% hyperbaric lidocaine)
Number of subjects: 28
Study: 8235870

Group type: EXPERIMENTAL
Intervention: Extension treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Flexion treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo-control treatment
Number of subjects: 56
Study: 3680597

Group type: EXPERIMENTAL
Intervention: 4-g dose of mezlocillin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-g dose of mezlocillin
Number of subjects: 12
Study: 30619530

Group type: EXPERIMENTAL
Intervention: Experiential module incorporating 10-minute practices of yoga, biofeedback, and acupressure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard lecture focused on CAIM use and outcomes
Number of subjects: 38
Study: 27133008

Group type: EXPERIMENTAL
Intervention: Retropubic sling or transobturator sling for stress urinary incontinence
Number of subjects: 526
Study: 24532039

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily (after switching from imatinib)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily (after switching from nilotinib 300 mg)
Number of subjects: 54
Study: 21740603

Group type: EXPERIMENTAL
Intervention: Parent-led intervention group (cognitive behavioural training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All children (after intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parents' report
Number of subjects: 50
Study: 20197582

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (including antiplatelet and antithrombin agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological and nonpharmacological strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 0
Study: 18597899

Group type: EXPERIMENTAL
Intervention: Lento music intervention (40-min group-based)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Silence (regular test without music)
Number of subjects: 38
Study: 15739719

Group type: EXPERIMENTAL
Intervention: Daily 15‐minute oral stimulation program for 10 days before the start of oral feedings
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no oral stimulation program)
Number of subjects: 32
Study: 14969216

Group type: EXPERIMENTAL
Intervention: Immediate non-occlusal loading of dental implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early loading protocol
Number of subjects: 0
Study: 10651785

Group type: EXPERIMENTAL
Intervention: IFT 3 (10‐20 Hz beat frequency)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no suction nor interferential current applied)
Number of subjects: 50